Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.

Ottoboni L, Keenan BT, Tamayo P, Kuchroo M, Mesirov JP, Buckle GJ, Khoury SJ, Hafler DA, Weiner HL, De Jager PL.

Sci Transl Med. 2012 Sep 26;4(153):153ra131.

PMID:
23019656
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Johnston J, So TY.

Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Review.

PMID:
22642799
[PubMed - indexed for MEDLINE]
3.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
[PubMed - indexed for MEDLINE]
4.

Glatiramer acetate (Copaxone).

Francis DA.

Int J Clin Pract. 2001 Jul-Aug;55(6):394-8. Review.

PMID:
11501229
[PubMed - indexed for MEDLINE]
5.

Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management.

Stuart WH.

J Manag Care Pharm. 2004 Jun;10(3 Suppl B):S19-25. Review.

PMID:
15253686
[PubMed - indexed for MEDLINE]
Free Article
6.

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

Yong VW.

Neurology. 2002 Sep 24;59(6):802-8. Review.

PMID:
12349849
[PubMed - indexed for MEDLINE]
7.

[Interferon -beta therapy in multiple sclerosis].

Satoh J.

Nihon Rinsho. 2006 Jul;64(7):1297-309. Review. Japanese.

PMID:
16838648
[PubMed - indexed for MEDLINE]
8.

Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.

Foti Cuzzola V, Palella E, Celi D, Barresi M, Giacoppo S, Bramanti P, Marino S.

Pharmacogenomics J. 2012 Dec;12(6):453-61. doi: 10.1038/tpj.2012.41. Epub 2012 Oct 9. Review.

PMID:
23044601
[PubMed - indexed for MEDLINE]
9.

A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis.

Zhang J, Hutton G, Zang Y.

Clin Ther. 2002 Dec;24(12):1998-2021. Review.

PMID:
12581542
[PubMed - indexed for MEDLINE]
10.

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.

Dhib-Jalbut S.

Neurology. 2002 Apr 23;58(8 Suppl 4):S3-9. Review.

PMID:
11971121
[PubMed - indexed for MEDLINE]
11.

Differential gene expression and translational approaches to identify biomarkers of interferon beta activity in multiple sclerosis.

Croze E.

J Interferon Cytokine Res. 2010 Oct;30(10):743-9. doi: 10.1089/jir.2010.0022. Review.

PMID:
20874251
[PubMed - indexed for MEDLINE]
12.

Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.

Neuhaus O, Stüve O, Archelos JJ, Hartung HP.

J Neurol Sci. 2005 Jun 15;233(1-2):173-7. Epub 2005 Apr 20. Review.

PMID:
15949504
[PubMed - indexed for MEDLINE]
13.

Current approved options for treating patients with multiple sclerosis.

Rizvi SA, Agius MA.

Neurology. 2004 Dec 28;63(12 Suppl 6):S8-14. Review.

PMID:
15623672
[PubMed - indexed for MEDLINE]
14.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Clerico M, Faggiano F, Palace J, Rice G, Tintorè M, Durelli L.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005278. doi: 10.1002/14651858.CD005278.pub3. Review.

PMID:
18425915
[PubMed - indexed for MEDLINE]
15.

Interferon-β-1b: a review of its use in multiple sclerosis.

Plosker GL.

CNS Drugs. 2011 Jan;25(1):67-88. doi: 10.2165/11206430-000000000-00000. Review.

PMID:
21128695
[PubMed - indexed for MEDLINE]
16.

Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy.

Verweij CL, Vosslamber S.

Discov Med. 2013 Jan;15(80):51-60. Review.

PMID:
23375014
[PubMed - indexed for MEDLINE]
Free Article
17.

The importance of early diagnosis of multiple sclerosis.

Miller JR.

J Manag Care Pharm. 2004 Jun;10(3 Suppl B):S4-11. Review.

PMID:
15253684
[PubMed - indexed for MEDLINE]
Free Article
18.

Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.

Qizilbash N, Mendez I, Sanchez-de la Rosa R.

Clin Ther. 2012 Jan;34(1):159-176.e5. doi: 10.1016/j.clinthera.2011.12.006. Review.

PMID:
22284996
[PubMed - indexed for MEDLINE]
19.

[Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].

Correale J, Cristiano E.

Medicina (B Aires). 2001;61(4):470-80. Review. Spanish.

PMID:
11563177
[PubMed - indexed for MEDLINE]
20.

Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.

Pender MP, Wolfe NP.

Intern Med J. 2002 Nov;32(11):554-63. Review.

PMID:
12412939
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk